U.K. regulators will grant marketing approval to Horizon Pharma's arthritis combination pill, pending review of a few final documents, the company said Friday.

Duexis is used to treat osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, an inflammatory disease of the spinal bones. The pill combines a prescription-strength dose of ibuprofen with a dose of famotidine, which is intended to prevent stomach ulcers associated with ibuprofen.

Duexis was previously approved in the U.S.

Shares of Horizon Pharma Inc. fell 3 cents, or 1.2 percent, to $2.37.